In a call last August or September Nader admitted that the price structure of the Vyera licensing deal for HIV in the US essentially killed any chance for a partnership on other indications. There is a price floor in the Vyera contract which extends to any indication, I believe it's somewhere around $40K - $60K annually per patient, that bigger pharma balked at. So the Vyera deal, which sounded kind of decent when it was signed, has been a hindrance. There has been talk of licensing outside the US but nothing ever came of it.
And yeah, obviously Nader sees himself as a bigtimer. He probably could have made a deal with a larger pharma for HIV but he went with the rinky dink, formerly run by Martin Shkreli, currently getting sued by everybody Vyera because Cytodyn will keep a much bigger slice of the pie if they ever have HIV revenue than a bigger pharma would take. But as a tradeoff, he got essentially nothing up front where a bigger pharma would have made sure Cytodyn was well capitalized to go for HIV approval.
Leronlimab and Nader are one and the same and he's made sure nobody is in a position to do anything about it. The Board never has. Past shareholders votes on contentious issues have always gone Nader's way so I'm not sure even a decent buyout offer would have the votes to pass.